• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

JAK2 V617F突变导致年轻患者门静脉血栓形成:一例报告

JAK2 V617F Mutation Leading to Portal Vein Thrombosis in a Young Patient: A Case Report.

作者信息

Patil Chandrashekar, Ananthu Venkata Ramya, Junaid Mohd Abdul Haq, Lavanya Polneni, Jabeen Safiya

机构信息

Radiodiagnosis, Malla Reddy Medical College for Women, Hyderabad, IND.

出版信息

Cureus. 2024 Dec 28;16(12):e76547. doi: 10.7759/cureus.76547. eCollection 2024 Dec.

DOI:10.7759/cureus.76547
PMID:39877786
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11772894/
Abstract

Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders commonly characterized by excessive production of blood cell lineages. The JAK2 V617F mutation plays a crucial role in the pathogenesis of these conditions, often leading to thrombotic complications. Here, we present the case of a 21-year-old man who presented with acute abdominal pain and was found to have portal vein thrombosis with splenomegaly. Imaging studies confirmed chronic portal vein thrombosis with extensive collateral circulation. Laboratory evaluation revealed an elevated platelet count, and genetic testing confirmed the presence of the JAK2 V617F mutation, suggestive of essential thrombocythemia. The patient was managed with anticoagulation (apixaban) and cytoreductive therapy (hydroxyurea). This case emphasizes the importance of considering underlying MPNs in young patients presenting with unusual thrombotic events, and highlights the significance of early diagnosis and targeted treatment in improving patient outcomes.

摘要

骨髓增殖性肿瘤(MPNs)是一类克隆性造血干细胞疾病,通常以血细胞系过度增殖为特征。JAK2 V617F突变在这些疾病的发病机制中起关键作用,常导致血栓形成并发症。在此,我们报告一例21岁男性患者,该患者因急性腹痛就诊,检查发现存在门静脉血栓形成并伴有脾肿大。影像学检查证实为慢性门静脉血栓形成并伴有广泛的侧支循环。实验室检查显示血小板计数升高,基因检测证实存在JAK2 V617F突变,提示原发性血小板增多症。该患者接受了抗凝治疗(阿哌沙班)和细胞减灭治疗(羟基脲)。本病例强调了对于出现不寻常血栓事件的年轻患者考虑潜在MPNs的重要性,并突出了早期诊断和靶向治疗对改善患者预后的意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1e8/11772894/d97cbac2acfd/cureus-0016-00000076547-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1e8/11772894/d97cbac2acfd/cureus-0016-00000076547-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1e8/11772894/d97cbac2acfd/cureus-0016-00000076547-i01.jpg

相似文献

1
JAK2 V617F Mutation Leading to Portal Vein Thrombosis in a Young Patient: A Case Report.JAK2 V617F突变导致年轻患者门静脉血栓形成:一例报告
Cureus. 2024 Dec 28;16(12):e76547. doi: 10.7759/cureus.76547. eCollection 2024 Dec.
2
Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.JAK2 V617F突变对布加综合征和/或门静脉血栓形成患者潜在慢性骨髓增殖性疾病的诊断价值。
Turk J Gastroenterol. 2015 Jan;26(1):42-8. doi: 10.5152/tjg.2015.5738.
3
JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease.JAK2 V617F 阳性潜伏性原发性血小板增多症与内脏静脉血栓形成:骨髓活检在骨髓增殖性疾病诊断中的作用
Acta Haematol. 2009;121(4):218-20. doi: 10.1159/000221962. Epub 2009 May 29.
4
Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis.韩国门脉高压症患者中显性骨髓增殖性肿瘤和 JAK2 V617F 突变的流行情况。
Int J Lab Hematol. 2011 Oct;33(5):471-6. doi: 10.1111/j.1751-553X.2011.01308.x. Epub 2011 Mar 24.
5
Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.JAK2 基因突变缺失是否是原发性血小板增多症出血的一个危险因素?对 106 例患者的分析。
Blood Transfus. 2010 Jan;8(1):21-7. doi: 10.2450/2009.0004-09.
6
JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature.JAK2(V617F)阳性早期骨髓增殖性疾病(原发性血小板增多症)作为两名中年女性门静脉血栓形成的原因:基于文献的治疗意义
Ann Hematol. 2007 Nov;86(11):793-800. doi: 10.1007/s00277-007-0351-1. Epub 2007 Aug 9.
7
..
Radiol Case Rep. 2018 Sep 20;13(6):1249-1255. doi: 10.1016/j.radcr.2018.08.023. eCollection 2018 Dec.
8
Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.内脏或脑静脉血栓形成且无明显慢性骨髓增殖性疾病患者中JAK2 V617F突变的发生率。
J Thromb Haemost. 2007 Apr;5(4):708-14. doi: 10.1111/j.1538-7836.2007.02424.x. Epub 2007 Jan 29.
9
Janus Kinase-2 Mutation Associated Portal Vein Thrombosis Complicating Liver Cirrhosis and Hepatocellular Carcinoma.Janus 激酶-2 突变相关门静脉血栓形成,并发肝硬化和肝细胞癌。
Asian Pac J Cancer Prev. 2021 Jan 1;22(1):267-275. doi: 10.31557/APJCP.2021.22.1.267.
10
JAK2 (V617F) Positive Latent Myeloproliferative Neoplasm Presenting with Splanchnic Vein Thrombosis.伴有内脏静脉血栓形成的JAK2(V617F)阳性潜伏性骨髓增殖性肿瘤
Indian J Hematol Blood Transfus. 2014 Sep;30(Suppl 1):4-8. doi: 10.1007/s12288-012-0215-2. Epub 2012 Dec 18.

本文引用的文献

1
..
Radiol Case Rep. 2018 Sep 20;13(6):1249-1255. doi: 10.1016/j.radcr.2018.08.023. eCollection 2018 Dec.
2
Myeloproliferative neoplasms and thrombosis.骨髓增殖性肿瘤与血栓。
Blood. 2013 Sep 26;122(13):2176-84. doi: 10.1182/blood-2013-03-460154. Epub 2013 Jul 3.
3
Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.骨髓增殖性肿瘤:分子病理生理学、必要的临床理解和治疗策略。
J Clin Oncol. 2011 Feb 10;29(5):573-82. doi: 10.1200/JCO.2010.29.8711. Epub 2011 Jan 10.
4
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.聚乙二醇化干扰素-α-2a在真性红细胞增多症中可诱导完全血液学和分子反应,且毒性较低。
Blood. 2008 Oct 15;112(8):3065-72. doi: 10.1182/blood-2008-03-143537. Epub 2008 Jul 23.
5
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.JAK2在骨髓增殖性疾病发病机制及治疗中的作用。
Nat Rev Cancer. 2007 Sep;7(9):673-83. doi: 10.1038/nrc2210.
6
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.人类骨髓增殖性疾病中酪氨酸激酶JAK2的获得性突变。
Lancet. 2005;365(9464):1054-61. doi: 10.1016/S0140-6736(05)71142-9.
7
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.真性红细胞增多症和原发性血小板增多症患者的预期寿命及生存预后因素。
Am J Med. 2004 Nov 15;117(10):755-61. doi: 10.1016/j.amjmed.2004.06.032.